Endonovo: Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis
February 01 2018 - 9:52AM
InvestorsHub NewsWire
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™
Reduced Infarct Size and Inhibited Fibrosis following Myocardial
Infarction
Los Angeles, CA -- February 01, 2018 -- InvestorsHub
NewsWire -- Endonovo Therapeutics, Inc. (OTCQB:
ENDV) ("Endonovo" or the "Company"), a commercial-stage developer
of non-invasive wearable Electroceutical™ devices, today announced
positive results from a study of post-myocardial infarction
remodeling in mice.
In the study, animals treated with the Company's non-invasive
medical device one or two times per day for 28 days had
significantly smaller (by 36.4%, p<0.01) infarcts versus the
controls. Furthermore, animals treated with Pulsed Electromagnetic
Fields (PEMF) one or two times per day for 28 days demonstrated
significantly less cardiac fibrosis than the controls.
Blood levels of Brain Natriuretic Peptide (BNP), a hormone
secreted by cardiomyocytes in the heart in response to volume
expansion and pressure overload, were significantly higher in
animals treated two times per day with PEMF versus the controls.
Natriuretic peptides have been shown to be Cardioprotective,
anti-fibrotic and paracrine regulators of vascular regeneration.
The Company is currently conducting a follow-up study to elucidate
a possible mechanism of action of PEMF treatment. Specifically, the
Company is examining if PEMF treatment promotes cardiomyocyte
survival and wound repair (angiogenesis), and inhibits excessive
inflammation in the infarcted heart.
The Company had previously announced initial pre-clinical data
demonstrating Immunotronics™ significantly improved cardiac
function, including ejection fraction and fractional shortening,
and reduced ventricular remodeling in infarcted animals following
myocardial infarction.
Left ventricular (LV) remodeling after myocardial infarction
(MI) includes infarct expansion and hypertrophy of the
non-infarcted myocardium, fibrosis, LV chamber dilatation, LV
functional deterioration and progression to heart failure.
Treatments targeting the remodeling process, such as beta-blockers
and angiotensin converting enzyme inhibitors have been shown to
improve LV function as well as long term survival. However, a slow
progression to chronic heart failure continues with large
transmural MI as the loss of infarcted tissue and volume overload
(chamber dilation) is often out of proportion to the hypertrophic
response. Therefore, new treatments that can further improve the
remodeling process are critical for preventing heart failure
following MI.
"We are truly astounded by the results of this study to evaluate
the effectiveness of our Electroceuticals in improving heart
function and reducing ventricular remodeling following MI," stated
Endonovo CEO, Alan Collier.
"Our team has seen the benefits of non-invasive Electroceuticals
in a clinical setting in patients with end-stage ischemic heart
disease using our 27.12 MHz tPEMF platform. We have now taken over
twenty years of research and development and have created a new
technology that we believe is a more effective treatment for
cardiovascular disease."
"We believe bioelectronic medicine is the future and our
non-invasive Electroceuticals™ are at the forefront of this
emerging field of medicine seeking to treat some of our largest
causes of death, including cardiovascular and cerebrovascular
disease with technology rather than drugs," concluded Mr. Collier.
The Company has posted an updated presentation containing the
results of its pre-clinical study on
the Presentations section of its website.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of
non-invasive wearable Electroceuticals™. The Company's current
portfolio of commercial and clinical-stage wearable
Electroceuticals™ addresses wound healing, pain, post surgical
edema and Central Nervous System (CNS) Disorders, including
traumatic brain injury (TBI), acute concussions, post-concussion
syndrome and multiple sclerosis. The Company's non-invasive
Electroceutical™ device using pulsed short-wave radiofrequency at
27.12 MHz has been FDA-Cleared and CE Marked for the palliative
treatment of soft tissue injuries and post-operative pain and
edema, and has CMS National Coverage for the treatment of chronic
wounds. The Company's current portfolio of pre-clinical stage
Electroceuticals™ addresses chronic kidney disease, liver disease,
cardiovascular and peripheral artery disease. The Company's
non-invasive, wearable Electroceuticals™ work by restoring key
electrochemical processes that initiate anti-inflammatory and
growth factor cascades necessary for healing to occur.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained
in this press release including words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," and other
similar expressions of opinion, constitute forward-looking
statements. Any such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any future results described within the forward-looking
statements. Risk factors that could contribute to such differences
include those matters more fully disclosed in the Company's reports
filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the
Company's estimates as of the date of the press release, and
subsequent events and developments may cause the Company's
estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied
upon as representing the Company's estimates of its future
financial performance as of any date subsequent to the date of this
press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
Source: Endonovo Therapeutics, Inc.
Investors: Sign Up for Email Alerts on Endonovo